JP2004529963A - 細胞傷害性ｃｄ４４抗体免疫コンジュゲート - Google Patents

細胞傷害性ｃｄ４４抗体免疫コンジュゲート Download PDF

Info

Publication number
JP2004529963A
JP2004529963A JP2002591041A JP2002591041A JP2004529963A JP 2004529963 A JP2004529963 A JP 2004529963A JP 2002591041 A JP2002591041 A JP 2002591041A JP 2002591041 A JP2002591041 A JP 2002591041A JP 2004529963 A JP2004529963 A JP 2004529963A
Authority
JP
Japan
Prior art keywords
compound
antibody molecule
antibody
conjugate
maytansinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002591041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529963A5 (enExample
Inventor
ギユンテル アドルフ
カールーハインツ ハイデル
エリク パッツエルト
マーリーズ シュプロール
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2004529963A publication Critical patent/JP2004529963A/ja
Publication of JP2004529963A5 publication Critical patent/JP2004529963A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2002591041A 2001-05-18 2002-05-16 細胞傷害性ｃｄ４４抗体免疫コンジュゲート Pending JP2004529963A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112227A EP1258255A1 (en) 2001-05-18 2001-05-18 Conjugates of an antibody to CD44 and a maytansinoid
PCT/EP2002/005413 WO2002094325A2 (en) 2001-05-18 2002-05-16 Cytotoxic cd44 antibody immunoconjugates

Publications (2)

Publication Number Publication Date
JP2004529963A true JP2004529963A (ja) 2004-09-30
JP2004529963A5 JP2004529963A5 (enExample) 2006-01-05

Family

ID=8177473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002591041A Pending JP2004529963A (ja) 2001-05-18 2002-05-16 細胞傷害性ｃｄ４４抗体免疫コンジュゲート

Country Status (24)

Country Link
EP (2) EP1258255A1 (enExample)
JP (1) JP2004529963A (enExample)
KR (1) KR20030097883A (enExample)
CN (1) CN1509187A (enExample)
AR (1) AR035977A1 (enExample)
BG (1) BG108366A (enExample)
BR (1) BR0209862A (enExample)
CA (1) CA2443438A1 (enExample)
CO (1) CO5550468A2 (enExample)
CZ (1) CZ20033477A3 (enExample)
EA (1) EA200301159A1 (enExample)
EE (1) EE200300568A (enExample)
HR (1) HRP20030932A2 (enExample)
HU (1) HUP0400046A3 (enExample)
IL (1) IL157965A0 (enExample)
MX (1) MXPA03010432A (enExample)
NO (1) NO20035108D0 (enExample)
NZ (1) NZ530167A (enExample)
PE (1) PE20021097A1 (enExample)
PL (1) PL365480A1 (enExample)
SK (1) SK15582003A3 (enExample)
WO (1) WO2002094325A2 (enExample)
YU (1) YU91503A (enExample)
ZA (1) ZA200307364B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523062A (ja) * 2004-12-09 2008-07-03 セントカー・インコーポレーテツド 抗インテグリン免疫コンジュゲート、方法および使用
JP2008531484A (ja) * 2005-02-11 2008-08-14 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
JP2016501858A (ja) * 2012-11-21 2016-01-21 アムキュア ゲーエムベーハー 転移性癌を処置するためのｃｄ４４ｖ６由来ペプチド
JP2016501857A (ja) * 2012-11-21 2016-01-21 アムキュア ゲーエムベーハー 膵癌を処置するためのｃｄ４４ｖ６由来ペプチド
JP2021519608A (ja) * 2018-02-22 2021-08-12 マルティチュード・インコーポレーテッド 治療抗体およびその使用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
PL1651162T3 (pl) * 2003-05-20 2016-04-29 Immunogen Inc Maitansynoidy w leczeniu nowotworów
ATE496944T1 (de) * 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
CA2893252C (en) 2005-08-24 2018-05-29 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
EP1806365A1 (en) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
ME03479B (me) 2009-06-03 2020-01-20 Immunogen Inc Metodi konjugacije
UY32913A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
KR102306490B1 (ko) 2013-03-15 2021-09-28 리제너론 파아마슈티컬스, 인크. 생물학적 활성 분자, 그의 접합체 및 치료 용도
SG11201601230RA (en) 2013-08-26 2016-03-30 Regeneron Pharma Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
WO2016150521A1 (en) * 2015-03-26 2016-09-29 Fundación Imdea Nanociencia Functionalised magnetic nanoparticle
CN107995912A (zh) 2015-03-27 2018-05-04 里珍纳龙药品有限公司 美登素类衍生物、其偶联物和使用方法
WO2017214151A1 (en) 2016-06-06 2017-12-14 Northwestern University Fusion protein construct
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19648209A1 (de) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Verfahren zur Tumorzelldepletion CD34-positiver Zellen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
EP2977063A1 (en) * 1999-06-25 2016-01-27 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1229934B1 (en) * 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523062A (ja) * 2004-12-09 2008-07-03 セントカー・インコーポレーテツド 抗インテグリン免疫コンジュゲート、方法および使用
JP2008531484A (ja) * 2005-02-11 2008-08-14 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
JP2016501858A (ja) * 2012-11-21 2016-01-21 アムキュア ゲーエムベーハー 転移性癌を処置するためのｃｄ４４ｖ６由来ペプチド
JP2016501857A (ja) * 2012-11-21 2016-01-21 アムキュア ゲーエムベーハー 膵癌を処置するためのｃｄ４４ｖ６由来ペプチド
JP2021519608A (ja) * 2018-02-22 2021-08-12 マルティチュード・インコーポレーテッド 治療抗体およびその使用

Also Published As

Publication number Publication date
CZ20033477A3 (en) 2004-05-12
NZ530167A (en) 2005-10-28
CN1509187A (zh) 2004-06-30
EE200300568A (et) 2004-04-15
IL157965A0 (en) 2004-03-28
ZA200307364B (en) 2004-04-20
PL365480A1 (en) 2005-01-10
CO5550468A2 (es) 2005-08-31
WO2002094325A2 (en) 2002-11-28
EP1395290A2 (en) 2004-03-10
KR20030097883A (ko) 2003-12-31
BG108366A (bg) 2004-09-30
PE20021097A1 (es) 2003-02-13
BR0209862A (pt) 2004-06-08
MXPA03010432A (es) 2004-04-02
EA200301159A1 (ru) 2004-06-24
NO20035108L (no) 2003-11-17
EP1258255A1 (en) 2002-11-20
HUP0400046A2 (hu) 2004-04-28
AR035977A1 (es) 2004-07-28
CA2443438A1 (en) 2002-11-28
HRP20030932A2 (en) 2004-04-30
HUP0400046A3 (en) 2006-02-28
WO2002094325A3 (en) 2003-04-17
YU91503A (sh) 2006-05-25
SK15582003A3 (sk) 2004-04-06
NO20035108D0 (no) 2003-11-17

Similar Documents

Publication Publication Date Title
JP2004529963A (ja) 細胞傷害性ｃｄ４４抗体免疫コンジュゲート
US7361347B2 (en) Cytotoxic CD44 antibody immunoconjugates
EP1391213A1 (en) Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP2004696B1 (en) Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US20050244413A1 (en) Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
Blakey et al. Antibody toxin conjugates: a perspective
JP2024517776A (ja) ネクチン－４を標的とする抗体薬物コンジュゲート並びにその調製方法及びその使用
EP1045861B1 (en) Bispecific targeting moiety comprising an antibody to carcinoembryonic antigen (cea) and the ligand-binding region of the il13 receptor alpha subunit
US20200188525A1 (en) Anti-egfr antibody drug conjugates (adc) and uses thereof
KR20250137203A (ko) 항체 약물 접합체
EP3675908A1 (en) Anti-egfr antibody drug conjugates (adc) and uses thereof
US20040120949A1 (en) Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
EP1417974A1 (en) Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
AU2002313471A1 (en) Cytotoxic CD44 antibody immunoconjugates
KR20220082846A (ko) B-림프구 특이적 아마톡신 항체 접합체
WO2024193605A1 (zh) 靶向ror1的抗体、包含其的抗体偶联药物、制备方法和用途
WO2023190827A1 (ja) ｐＨ依存性抗硫酸化グリコサミノグリカン抗体及び抗体薬物複合体
WO2024251743A1 (en) Dual payload antibody drug conjugates for the treatment of cancer
Dosio et al. Targeted Cancer Therapy: The Roles Played by Antibody-Drug and Antibody-Toxin Conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090914